Galera Therapeutics, Inc. (GRTX) Stock Price & Analysis
Galera Therapeutics, Inc. (GRTX) fell 2.00% to USD 0.09 as of June 10, 2026 at 03:10 UTC, according to Nexqual real-time market data.
GRTX last closed at USD 0.1; the session ranged USD 0.09–0.09 on volume of 30,132 shares. Market capitalization is $18.92M, with a 52-week range of USD 0.02–0.15 (OQB). Source: Nexqual, June 10, 2026 at 03:10 UTC.
Key Statistics (as of June 10, 2026 at 03:10 UTC)
| Price | USD 0.09 |
|---|---|
| Change | ▼ 2.00% (down) |
| Previous Close | USD 0.1 |
| Open | USD 0.09 |
| Day Range | USD 0.09 – 0.09 |
| 52-Week Range | USD 0.02 – 0.15 |
| Volume | 30,132 shares |
| Market Cap | $18.92M |
| Exchange | OQB |
Technical Analysis (GRTX)
Nexqual's technical model rates GRTX "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 03:10 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 39.56 (neutral) |
| vs SMA50 | Above (USD 0.09) |
| MACD | 0 (positive) |
Analyst Ratings (GRTX)
Wall Street analysts rate GRTX "None", per Nexqual as of June 10, 2026 at 03:10 UTC.
| Consensus Rating | None |
|---|
Earnings (GRTX)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -0.33 vs est -0.4 ▲ beat |
| 2023-06-30 | USD -0.48 vs est -0.38 ▼ miss |
| 2023-03-31 | USD -0.5 vs est -0.43 ▼ miss |
| 2022-12-31 | USD -0.58 vs est -0.51 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:10 UTC.
Financials & Fundamentals (GRTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 5.31 |
| Total Cash | $5.50M |
| Total Debt | $0 |
| Free Cash Flow | $-2.76M |
Source: Nexqual, June 10, 2026 at 03:10 UTC.
Financial Health Score (GRTX)
Nexqual rates Galera Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $6M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$5M |
| Efficiency | Mixed — No data |
Ownership (GRTX)
| Insider Ownership | +34.47% |
|---|---|
| Institutional Ownership | +3.71% |
| Shares Outstanding | 203.27M |
| Float | 70.92M |
| Short % of Float | +5.28% |
Source: Nexqual, June 10, 2026 at 03:10 UTC.
Leadership (GRTX)
Galera Therapeutics, Inc. is led by J. Mel Sorensen (age 68), CEO, President & Chairman, per Nexqual as of June 10, 2026 at 03:10 UTC.
| CEO, President & Chairman | J. Mel Sorensen (age 68) |
|---|
From Galera Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer.
- The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC).
- It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals, Inc. | USD 0.01 | ▲ 8.33% |
| BFRI | Biofrontera Inc. | USD 0.88 | ▼ 5.88% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 0% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.58 | ▼ 0.85% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:10 UTC. This page is informational and not investment advice.